Trial · NCT06331000
Effect of One Year Elexacaftor-tezacaftor-ivacaftor Treatment
NCT06331000, Completed, University Hospital, Strasbourg, France
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effect of One Year Elexacaftor-tezacaftor-ivacaftor Treatment. Trials, record NCT06331000. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06331000
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effect of One Year Elexacaftor-tezacaftor-ivacaftor Treatment
- NCT number
- NCT06331000
- Status
- Completed
- Enrollment
- 184 participants, actual
- Lead sponsor
- University Hospital, Strasbourg, France
- Conditions
- Cystic Fibrosis
- Interventions
- elexacaftor-tezacaftor-ivacaftor treatment
- First posted
- 2024-03-26
- Last updated
- 2025-05-08
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluate time in range of blood glucose variation >140 mg/dl during 2 weeks in a cohort of adult patients treated for one year with elexacaftor-tezacaftor-ivacaftor | time in range of blood glucose variation >140 mg/dl one year before and one year after the begining of elexacaftor-tezacaftor-ivacaftor treatment | |
| Secondary | Evaluate other CGM parameters : time in range of blood glucose >180mg/dl ; >140mg/dl ; <70mg/dl ; 70-180 mg/dl ; 70-140mg/dl | One year before and one year after the start of elexacaftor-tezacaftor-ivacaftor treatment | |
| Secondary | Marker of metabolic status: HbA1c (mmol/l) | One year before and one year after the start of elexacaftor-tezacaftor-ivacaftor treatment | |
| Secondary | Marker of metabolic status: HbA1c (%) | One year before and one year after the start of elexacaftor-tezacaftor-ivacaftor treatment | |
| Secondary | Marker of metabolic status: C-Peptid (µg/L) | One year before and one year after the start of elexacaftor-tezacaftor-ivacaftor treatment | |
| Secondary | Marker of metabolic status: C-Peptid (nmol/L) | One year before and one year after the start of elexacaftor-tezacaftor-ivacaftor treatment | |
| Secondary | Markers of nutritional status: Evaluation of weight monitoring (kg) | One year before and one year after the start of elexacaftor-tezacaftor-ivacaftor treatment | |
| Secondary | Markers of nutritional status: Body Mass Index (BMI) | One year before and one year after the start of elexacaftor-tezacaftor-ivacaftor treatment | |
| Secondary | Diabetes treatment (assess insulin needs) : mean glucose value per day (mg/dl) | One year before and one year after the start of elexacaftor-tezacaftor-ivacaftor treatment | |
| Secondary | Assessment of respiratory function parameters : number of IV antibiotics | One year before and one year after the start of elexacaftor-tezacaftor-ivacaftor treatment |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06331000
GET https://conductscience.org/api/trials/v1/NCT06331000/registered